Definium Therapeutics (DFTX) Current Assets (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Current Assets data on file, last reported at $380.6 million in Q1 2026.

• Quarterly Current Assets rose 71.66% year-over-year to $380.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $380.6 million (up 71.66% YoY) and the FY2025 annual result came in at $419.3 million, up 48.9% from the prior year.
• Current Assets eased to $380.6 million in Q1 2026 per DFTX's latest filing, from $419.3 million in the prior quarter.
• Across five years, Current Assets topped out at $419.3 million in Q4 2025 and bottomed at $103.9 million in Q4 2023.
• The 5-year median for Current Assets is $189.1 million (2025), against an average of $207.2 million.
• The widest annual swing landed in 2022, when Current Assets slumped 31.2%; it then jumped 171.12% in 2024.
• Tracing DFTX's Current Assets over 5 years: stood at $146.1 million in 2022, then decreased by 28.88% to $103.9 million in 2023, then jumped by 171.12% to $281.6 million in 2024, then surged by 48.9% to $419.3 million in 2025, then slipped by 9.24% to $380.6 million in 2026.
• Per Business Quant, the three latest DFTX Current Assets figures stand at $380.6 million (Q1 2026), $419.3 million (Q4 2025), and $215.8 million (Q3 2025).

Peer Comparison